About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pickup

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

33.74 -0.16 (-0.46%)

Streaming Delayed Price Updated: 12:00 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024

From Genmab A/S

Via Business Wire

Genmab Completes Acquisition of ProfoundBio

May 21, 2024

From Genmab A/S

Via Business Wire

7 Biotech Stocks That Could Breathe New Life Into Your Portfolio ↗

May 20, 2024

Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.

Via InvestorPlace

What 9 Analyst Ratings Have To Say About Genmab ↗

May 20, 2024

Via Benzinga

NASDAQ:GMAB is showing good growth, while it is not too expensive. ↗

May 02, 2024

Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB).

Via Chartmill

Decoding 9 Analyst Evaluations For Genmab ↗

April 30, 2024

Via Benzinga

NASDAQ:GMAB is not too expensive for the growth it is showing. ↗

April 11, 2024

Via Chartmill

Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

May 14, 2024

From Genmab A/S

Via Business Wire

GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024 ↗

May 02, 2024

GMAB stock results show that Genmab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

April 29, 2024

From Genmab A/S

Via Business Wire

Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock? ↗

March 28, 2024

Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout.

Via Chartmill

Analyst Ratings For Genmab ↗

March 26, 2024

Via Benzinga

4 Analysts Assess Genmab: What You Need To Know ↗

February 20, 2024

Via Benzinga

Earnings Outlook For Genmab ↗

February 13, 2024

Via Benzinga

FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer

April 29, 2024

From Pfizer Inc.

Via Business Wire

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market ↗

April 25, 2024

The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.

Via Investor's Business Daily

ProfoundBio Discovers The Joys Of Having A Wealthy Owner ↗

April 08, 2024

Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a...

Via Benzinga

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗

April 06, 2024

ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...

Via Talk Markets

NASDAQ:GMAB, a strong growth stock, setting up for a breakout. ↗

February 08, 2024

Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

Cracking The Code: Understanding Analyst Reviews For Genmab ↗

January 29, 2024

Via Benzinga

Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio ↗

April 03, 2024

Genmab is buying a privately held company focused on antibody drug conjugates.

Via Investor's Business Daily

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

April 03, 2024

From Genmab A/S

Via Business Wire

NASDAQ:GMAB is showing good growth, while it is not too expensive. ↗

March 21, 2024

For those who appreciate growth without the sticker shock, GENMAB A/S -SP ADR (NASDAQ:GMAB) is worth considering.

Via Chartmill

Why NASDAQ:GMAB Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

March 05, 2024

Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

NASDAQ:GMAB is showing good growth, while it is not too expensive. ↗

February 29, 2024

While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.

Via Chartmill

Investors seeking growth at a reasonable cost should explore NASDAQ:GMAB. ↗

January 18, 2024

NASDAQ:GMAB is showing good growth, while it is not too expensive.

Via Chartmill

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

February 27, 2024

From Genmab A/S

Via Business Wire

Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. ↗

February 08, 2024

While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.

Via Chartmill

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

February 02, 2024

From Genmab A/S

Via Business Wire

What's Going On With Danish Healthcare Firm Genmab Stock? ↗

January 23, 2024

Genmab's legal update on Darzalex: Arbitrator dismisses bid for milestone payments. Despite this, diverse revenue sources, including royalty agreements, contribute to strong growth.

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Genmab A/S - American Depositary Shares (NQ:GMAB)

All News about Genmab A/S - American Depositary Shares

Sections

Services

Contact Information

Follow Us